Somatostatin-Immunoreactive Pancreaticoduodenal Neuroendocrine Neoplasms: Twenty-three cases evaluated according to the WHO 2010 Classification

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Somatostatin-Immunoreactive Pancreaticoduodenal Neuroendocrine Neoplasms : Twenty-three cases evaluated according to the WHO 2010 Classification. / Engelund Luna, Iben; Monrad, Nina; Binderup, Tina; Boisen Thoegersen, Christina; Hilsted, Linda; Jensen, Claus; Federspiel, Birgitte; Knigge, Ulrich.

In: Neuroendocrinology, Vol. 103, No. 5, 000441605, 2016, p. 567-77.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Engelund Luna, I, Monrad, N, Binderup, T, Boisen Thoegersen, C, Hilsted, L, Jensen, C, Federspiel, B & Knigge, U 2016, 'Somatostatin-Immunoreactive Pancreaticoduodenal Neuroendocrine Neoplasms: Twenty-three cases evaluated according to the WHO 2010 Classification', Neuroendocrinology, vol. 103, no. 5, 000441605, pp. 567-77. https://doi.org/10.1159/000441605

APA

Engelund Luna, I., Monrad, N., Binderup, T., Boisen Thoegersen, C., Hilsted, L., Jensen, C., ... Knigge, U. (2016). Somatostatin-Immunoreactive Pancreaticoduodenal Neuroendocrine Neoplasms: Twenty-three cases evaluated according to the WHO 2010 Classification. Neuroendocrinology, 103(5), 567-77. [000441605]. https://doi.org/10.1159/000441605

Vancouver

Engelund Luna I, Monrad N, Binderup T, Boisen Thoegersen C, Hilsted L, Jensen C et al. Somatostatin-Immunoreactive Pancreaticoduodenal Neuroendocrine Neoplasms: Twenty-three cases evaluated according to the WHO 2010 Classification. Neuroendocrinology. 2016;103(5):567-77. 000441605. https://doi.org/10.1159/000441605

Author

Engelund Luna, Iben ; Monrad, Nina ; Binderup, Tina ; Boisen Thoegersen, Christina ; Hilsted, Linda ; Jensen, Claus ; Federspiel, Birgitte ; Knigge, Ulrich. / Somatostatin-Immunoreactive Pancreaticoduodenal Neuroendocrine Neoplasms : Twenty-three cases evaluated according to the WHO 2010 Classification. In: Neuroendocrinology. 2016 ; Vol. 103, No. 5. pp. 567-77.

Bibtex

@article{eda4726b5355490c855e75b3b81de702,
title = "Somatostatin-Immunoreactive Pancreaticoduodenal Neuroendocrine Neoplasms: Twenty-three cases evaluated according to the WHO 2010 Classification",
abstract = "OBJECTIVE: Neuroendocrine neoplasms in the pancreas and duodenum with predominant or exclusive immunoreactivity for somatostatin (p-dSOMs) are rare, and knowledge on tumour biology, treatment, survival and prognostic factors is limited. This study aimes to describe clinical, pathological, and biochemical features as well as treatment and prognosis.DESIGN: Twenty-three patients with p-dSOM (9 duodenal, 12 pancreatic, 2 unknown primary tumour) were identified from our prospective neuroendocrine tumour (NET) database, and data according to the study aims were recorded.RESULTS: Of the 9 patients with duodenal SOM the m/f ratio was 4/5. All males and one female had NF-1. Seven patients had stage 1A-B and 2 had stage 2B disease. The Ki-67 index was 1-5{\%} (median 2{\%}). Plasma somatostatin was elevated in patients with 2B disease. Of the 14 patients with pancreatic SOM or unknown primary tumour the m/f ratio was 2/12. One male had MEN-1. Five had stage 1A-2B and nine had stage 4. The Ki-67 index was 1-40{\%} (median 7{\%}). Plasma somatostatin was elevated in seven patients. Patients reported symptoms related to the somatostatinoma syndrome, but none fulfilled the criteria for a full syndrome. Primary tumour in the pancreas, metastatic disease at diagnosis and higher tumour grade were all associated with a significantly poorer survival.CONCLUSION: None of the patients with p-dSOM presented with the full somatostatinoma syndrome. Prognostic factors are localisation of the primary tumour, dissemination and tumour grade. A Ki-67 of 5{\%} may discriminate the course of disease.",
author = "{Engelund Luna}, Iben and Nina Monrad and Tina Binderup and {Boisen Thoegersen}, Christina and Linda Hilsted and Claus Jensen and Birgitte Federspiel and Ulrich Knigge",
note = "{\circledC} 2015 S. Karger AG, Basel.",
year = "2016",
doi = "10.1159/000441605",
language = "English",
volume = "103",
pages = "567--77",
journal = "Neuroendocrinology",
issn = "0028-3835",
publisher = "S Karger AG",
number = "5",

}

RIS

TY - JOUR

T1 - Somatostatin-Immunoreactive Pancreaticoduodenal Neuroendocrine Neoplasms

T2 - Twenty-three cases evaluated according to the WHO 2010 Classification

AU - Engelund Luna, Iben

AU - Monrad, Nina

AU - Binderup, Tina

AU - Boisen Thoegersen, Christina

AU - Hilsted, Linda

AU - Jensen, Claus

AU - Federspiel, Birgitte

AU - Knigge, Ulrich

N1 - © 2015 S. Karger AG, Basel.

PY - 2016

Y1 - 2016

N2 - OBJECTIVE: Neuroendocrine neoplasms in the pancreas and duodenum with predominant or exclusive immunoreactivity for somatostatin (p-dSOMs) are rare, and knowledge on tumour biology, treatment, survival and prognostic factors is limited. This study aimes to describe clinical, pathological, and biochemical features as well as treatment and prognosis.DESIGN: Twenty-three patients with p-dSOM (9 duodenal, 12 pancreatic, 2 unknown primary tumour) were identified from our prospective neuroendocrine tumour (NET) database, and data according to the study aims were recorded.RESULTS: Of the 9 patients with duodenal SOM the m/f ratio was 4/5. All males and one female had NF-1. Seven patients had stage 1A-B and 2 had stage 2B disease. The Ki-67 index was 1-5% (median 2%). Plasma somatostatin was elevated in patients with 2B disease. Of the 14 patients with pancreatic SOM or unknown primary tumour the m/f ratio was 2/12. One male had MEN-1. Five had stage 1A-2B and nine had stage 4. The Ki-67 index was 1-40% (median 7%). Plasma somatostatin was elevated in seven patients. Patients reported symptoms related to the somatostatinoma syndrome, but none fulfilled the criteria for a full syndrome. Primary tumour in the pancreas, metastatic disease at diagnosis and higher tumour grade were all associated with a significantly poorer survival.CONCLUSION: None of the patients with p-dSOM presented with the full somatostatinoma syndrome. Prognostic factors are localisation of the primary tumour, dissemination and tumour grade. A Ki-67 of 5% may discriminate the course of disease.

AB - OBJECTIVE: Neuroendocrine neoplasms in the pancreas and duodenum with predominant or exclusive immunoreactivity for somatostatin (p-dSOMs) are rare, and knowledge on tumour biology, treatment, survival and prognostic factors is limited. This study aimes to describe clinical, pathological, and biochemical features as well as treatment and prognosis.DESIGN: Twenty-three patients with p-dSOM (9 duodenal, 12 pancreatic, 2 unknown primary tumour) were identified from our prospective neuroendocrine tumour (NET) database, and data according to the study aims were recorded.RESULTS: Of the 9 patients with duodenal SOM the m/f ratio was 4/5. All males and one female had NF-1. Seven patients had stage 1A-B and 2 had stage 2B disease. The Ki-67 index was 1-5% (median 2%). Plasma somatostatin was elevated in patients with 2B disease. Of the 14 patients with pancreatic SOM or unknown primary tumour the m/f ratio was 2/12. One male had MEN-1. Five had stage 1A-2B and nine had stage 4. The Ki-67 index was 1-40% (median 7%). Plasma somatostatin was elevated in seven patients. Patients reported symptoms related to the somatostatinoma syndrome, but none fulfilled the criteria for a full syndrome. Primary tumour in the pancreas, metastatic disease at diagnosis and higher tumour grade were all associated with a significantly poorer survival.CONCLUSION: None of the patients with p-dSOM presented with the full somatostatinoma syndrome. Prognostic factors are localisation of the primary tumour, dissemination and tumour grade. A Ki-67 of 5% may discriminate the course of disease.

U2 - 10.1159/000441605

DO - 10.1159/000441605

M3 - Journal article

C2 - 26505735

VL - 103

SP - 567

EP - 577

JO - Neuroendocrinology

JF - Neuroendocrinology

SN - 0028-3835

IS - 5

M1 - 000441605

ER -

ID: 162218179